Machine learning in cardiovascular CT has the potential to improve disease diagnosis and predictive models, according to the authors of a new paper, but limitations with its applications still remain.

Transfer times to an endovascular therapy-capable hospital are an average of 20 minutes slower during nighttime hours at one hub-and-spoke stroke network, possibly leading to a lower likelihood of those patients receiving thrombectomy.

While women are equally or overrepresented in clinical trials for hypertension, atrial fibrillation (AFib) and pulmonary arterial hypertension, they are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome, according to a new study published in the Journal of the American College of Cardiology.

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

Nearly 22 percent more physician specialty practices employed nurse practitioners or physician assistants in 2016 than they did in 2008, according to a research letter published April 30 in JAMA Internal Medicine.

Abbott’s XIENCE Sierra, the newest generation of the company’s everolimus-eluting coronary stent, has been approved for national reimbursement in Japan.

The American Heart Association (AHA)/American Stroke Association (ASA) is revisiting its recently updated stroke guidelines after issuing a “correction” that removed several portions.

A new nationwide study from Japan highlighted the importance of timely ambulance arrival, showing that bystander defibrillation and cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest are essentially worthless if EMS response times are slower than 13 minutes and 11 minutes, respectively.

Common therapies used in the treatment of psoriasis may help reduce coronary plaque, according to a new study presented April 26 at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions in San Diego.

Alteplase is sometimes administered to dissolve clots before endovascular thrombectomy in patients with ischemic stroke. But a new study in the New England Journal of Medicine demonstrates tenecteplase, a genetically modified form of alteplase, is associated with better blood flow restoration and improved functional outcomes.